UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Haematologica (Roma), 2012-11, Vol.97 (11), p.1761-1767

2012

Volltextzugriff (PDF)

Clinical value of molecular subtyping multiple myeloma using gene expression profiling

Leukemia, 2016-02, Vol.30 (2), p.423-430

2016

Volltextzugriff (PDF)

Effects of long-term nitrogen addition on phosphorus cycling in organic soil horizons of temperate forests

Biogeochemistry, 2018-11, Vol.141 (2), p.167-181

2018

Volltextzugriff (PDF)

Inhibiting MEK in MAPK pathway-activated myeloma

Leukemia, 2016-04, Vol.30 (4), p.976-980

2016

Volltextzugriff (PDF)

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

Leukemia, 2012-11, Vol.26 (11), p.2398-2405

2012

Volltextzugriff (PDF)

Serial exome analysis of disease progression in premalignant gammopathies

Leukemia, 2014-07, Vol.28 (7), p.1548-1552

2014

Volltextzugriff (PDF)

Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia

Leukemia, 2014-04, Vol.28 (4), p.888-893

2014

Volltextzugriff (PDF)

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

Leukemia, 2014-12, Vol.28 (12), p.2410-2413

2014

Volltextzugriff (PDF)

Electroless Deposition and Structuring of Silver Electrodes in Closed Microfluidic Capillaries

Journal of microelectromechanical systems, 2011-04, Vol.20 (2), p.451-459

2011

Volltextzugriff (PDF)

Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma

Leukemia, 2015-12, Vol.29 (12), p.2418-2421

2015

Volltextzugriff (PDF)

Low voltage electroosmotic pump for high density integration into microfabricated fluidic systems

Microfluidics and nanofluidics, 2011-06, Vol.10 (6), p.1317-1332

2011

Volltextzugriff (PDF)

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL‐1)

HemaSphere, 2023-05, Vol.7 (S2), p.26-27

2023

Volltextzugriff (PDF)

AB1194 Serum cartilage oligomeric matrix protein compared to articular cartilage thickness in children with juvenile idiopathic arthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.706-706

2013

Volltextzugriff (PDF)

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

Leukemia, 2015-08, Vol.29 (8), p.1713-1720

2015

Volltextzugriff (PDF)

OP0012 Chronic recurrent non-bacterial osteomyelitis in danish children

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.56-56

2013

Volltextzugriff (PDF)

Establishing traceability of photometric absorbance values for accurate measurements of the haemoglobin concentration in blood

Metrologia, 2013-10, Vol.50 (5), p.539-548

2013

Volltextzugriff (PDF)

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

Haematologica (Roma), 2013-07, Vol.98 (7), p.1147-1153

2013

Volltextzugriff (PDF)

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

Blood cancer journal (New York), 2016-07, Vol.6 (7), p.e453-e453

2016

Volltextzugriff (PDF)

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

Blood cancer journal (New York), 2016-09, Vol.6 (9), p.e471

2016

Volltextzugriff (PDF)

S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO‐ENVIRONMENT DURING MYELOMA DISEASE PROGRESSION

HemaSphere, 2022-06, Vol.6, p.71-72

2022

Volltextzugriff (PDF)

An Analytical Approach for Performance Evaluation of Hybrid (Broadcast/Mobile) Networks

IEEE transactions on broadcasting, 2010-03, Vol.56 (1), p.9-18

Heuck, C.

2010

Volltextzugriff (PDF)

A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide

Archives of disease in childhood, 2000-10, Vol.83 (4), p.334-339

2000

Volltextzugriff (PDF)

Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

Journal of cancer research and clinical oncology, 2021-02, Vol.147 (2), p.619-631

2021

Volltextzugriff (PDF)

1 – 25 von 232

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(160)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(132)
EZB Free E-Journals
(111)
Journals@Ovid Complete
(86)
Ingenta
(67)
Publisher website
(60)
2022 ECC(Springer)
(40)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(27)
Wiley-Blackwell Journals
(25)
Thieme - Connect here FIRST to enable access
(24)
Wiley Online Library Full Collection 2018
(21)
IngentaConnect Journals
(18)
Nature
(18)
Oxford University Press Journals Current
(15)
Oxford Journals 2020 Medicine
(14)
Taylor & Francis:Master (3349 titles)
(10)
Nexis Uni
(10)
Taylor & Francis Journals
(10)
Taylor & Francis
(10)
JSTOR
(9)
BMJ Journals
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Clinical value of molecular subtyping multiple myeloma using gene expression profiling

Effects of long-term nitrogen addition on phosphorus cycling in organic soil horizons of temperate forests

Inhibiting MEK in MAPK pathway-activated myeloma

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

Serial exome analysis of disease progression in premalignant gammopathies

Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

Electroless Deposition and Structuring of Silver Electrodes in Closed Microfluidic Capillaries

Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma

Low voltage electroosmotic pump for high density integration into microfabricated fluidic systems

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL‐1)

AB1194 Serum cartilage oligomeric matrix protein compared to articular cartilage thickness in children with juvenile idiopathic arthritis

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

OP0012 Chronic recurrent non-bacterial osteomyelitis in danish children

Establishing traceability of photometric absorbance values for accurate measurements of the haemoglobin concentration in blood

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO‐ENVIRONMENT DURING MYELOMA DISEASE PROGRESSION

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

An Analytical Approach for Performance Evaluation of Hybrid (Broadcast/Mobile) Networks

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide

Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

Aktive Filter

Suchergebnisse filtern